Skip to main content
HR 6155 116th Congress House Health Drug safety, medical device, and laboratory regulation Licensing and registrations Prescription drugs

To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.

Introduced: March 9, 2020 Introduced by: Grothman, Glenn Republican · Wisconsin See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 9, 2020
Referred to the House Committee on Energy and Commerce.
Mar 9, 2020
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

This bill requires the Food and Drug Administration (FDA) to continue to review applications for certain biological products under an earlier review process, notwithstanding recent FDA guidance. Specifically, the bill applies to applications that were filed under the earlier process on or before March 23, 2019, and were still pending on March 23, 2020. (A 2009 law established a new procedure for approving biological products but allowed certain products in an already approved product class to receive approval under the earlier procedure until March 23, 2020; subsequently, in December 2018, the FDA issued guidance stating that an application filed under the earlier procedure that is not approved by March, 23, 2020, will not be approved.)

What's happening now March 9, 2020

Referred to the House Committee on Energy and Commerce.

 Related & companion bills 3
  • HR 19 Related bill Lower Costs, More Cures Act of 2019
  • S 1895 Related bill Lower Health Care Costs Act
  • S 2103 Related bill Affordable Insulin Approvals Now Act
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 6155: To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.. 116th Congress. Open America. https://openamerica.io/bill/116-HR-6155/
MLA
"H.R. 6155: To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-6155/.
Bluebook (legal)
H.R. 6155, 116th Cong. (2026), https://openamerica.io/bill/116-HR-6155/.
Markdown link
[H.R. 6155: To amend the Biologics Price Competition and Innovation Act of 2009 to make improvements with respect to the transition of biological products, and for other purposes.](https://openamerica.io/bill/116-HR-6155/)
Report a problem